Express Pharma
Home  »  Latest Updates  »  Bispecific antibodies will mature after 2021, $6bn estimated sales in oncology by 2025: GlobalData

Bispecific antibodies will mature after 2021, $6bn estimated sales in oncology by 2025: GlobalData

There are 106 bispecific antibody molecules in the pipeline and 263 ongoing/planning to enrol clinical trials involving a bispecific antibody

0 150
Read Article

The clinical success of Amgen’s Blincyto has amplified the intensive pace of development for bispecific antibodies in oncology. According to GlobalData’s drugs database, there are 106 bispecific antibody molecules – with various targets – currently in the pipeline. Furthermore, there are 263 ongoing/planning to enrol clinical trials involving a bispecific antibody.

Sakis Paliouras, Oncology Analyst at GlobalData, comments, “Blincyto has revolutionised the treatment of acute lymphocytic leukaemia (ALL). This class of immuno-oncology drugs is typically used in the same context as CAR-T cells but has the inherent advantage of off-the-shelf delivery while promising a more precisely controlled safety profile. Major players such as Amgen, Roche, Regeneron and Johnson & Johnson are now invested in the development of bispecific antibodies for various cancers, with most of their ongoing trials involving blood cancers.”

Most bispecific antibodies are in an early phase of development, with 70 agents in Phase I compared to 36 in Phase II. This highlights the relative lack of maturity for this technology, however, it has great market potential. GlobalData estimates that the bispecific antibody sales in oncology will reach $6 billion by 2025.”

Of the 106 bispecific antibody agents that are currently in clinical development, 45 are purposed primarily for blood cancers and the rest for solid tumours – mainly gastrointestinal and lung cancers. The most prominent targets for bispecific antibodies are CD19, CD20 and BCMA in blood malignancies, and EGFR and HER2 in solid tumours. However, some agents may be intended for multiple cancer types. For example, mosunetuzumab has four ongoing clinical trials for various B-cell malignancies.

Furthermore, more than half of the 106 agents are bispecific T-cell engagers (BiTEs), binding the CD3 antigen in T-cells in order to promote an anti-tumour immune response.

Paliouras concludes, “Blincyto remains the only bispecific antibody approved for an oncology indication. While the field is still immature, GlobalData expects this to change in 2021 with a potential market entry of Roche’s mosunetuzumab for B-cell malignancies and multiple other new agents with potential approval in 2022.”

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image